ArticlePloS one2024
Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pre-operative injectable testosterone therapy is associated with increased five-year revision risk after total shoulder arthroplasty: a TriNetX database analysis.Journal of shoulder and elbow arthroplasty · 2026Article
- Testosterone Replacement Therapy is Associated With Increased Risk of Pseudarthrosis After Single-Level Anterior Cervical Discectomy and Fusion: A Propensity Matched Analysis.Global spine journal · 2026Article
- The Intersection of Androgens and Cardiovascular Disease in Postmenopausal Women.Current cardiology reports · 2026Review
- Testosterone Therapy and Tendon Injury: Clinical Evidence, Biological Mechanisms, and Sports Medicine Implications.Cureus · 2026Review
- Testosterone Therapy and Associated Rates of Tendon Tear and Surgical Repair: A Retrospective Analysis.Orthopaedic journal of sports medicine · 2026Article
- Higher Circulating Testosterone Linked to Higher CAD Risk in Men: Mendelian Randomization and Survival Analyses.The Journal of clinical endocrinology and metabolism · 2026Article
- Effect of Testosterone Therapy on Cytochrome P450 3A and P-Glycoprotein Activities Using Midazolam and Digoxin as Probe Substrates Among Transgender Adults.Pharmacotherapy · 2026Article
- Preoperative testosterone replacement therapy: a potential risk-factor for complications and reoperation after rotator cuff repair.JSES international · 2026Article
- Injectable Testosterone Replacement Therapy Within 1 Year Before ACL Reconstruction Is Associated With Increased Revision Rates.Orthopaedic journal of sports medicine · 2026Article
- Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies.Translational andrology and urology · 2025Review
- Navigating atrial fibrillation in an endurance athlete: Evaluation, risk stratification, lifestyle modifications, and therapeutic considerations.HeartRhythm case reports · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor two decades preceding the COVID-19 pandemic, testosterone therapy (TT) became more prevalent in the US. Given the forced shift in practice patterns and healthcare accessibility during the pandemic, it was unclear how TT utilization would change.
objectiveTo assess the change in testosterone prescriptions nationally.
designCross-sectional study. DATA SOURCES: State prescription drug monitoring program data between 2018 and 2022.
participantsAll individuals filling testosterone prescriptions in participating states. MEASUREMENTS: Unique people filling testosterone prescriptions annually, demographic information on gender and age as available.
resultsIn 2022 there was a 27% relative increase of subjects treated with TT (+439,659 cases compared with 2018). The increase was more evident in the pandemic period with a rise in prevalence most notable for people 45-54 (114,114 people, 35% increase) and 35-44 (97,263 people, 58% increase). All regions except the Midwest increased the total population treated, led by the South (52%) followed by the West (28%) and Northeast (23%). Available data indicated men accounted for most patients treated in all age groups except under 24 years. LIMITATIONS: Study population limited to those in participating states with no diagnostic information and limited demographics available.
conclusionBetween 2018 and 2022, and primarily after the start of the pandemic in 2020, nationally there was a substantial increase in the number of people using TT. The largest increases occurred in a younger demographic, primarily men, than have previously been reported or studied. These results echo other findings showing increased use of controlled substances during the pandemic period and warrant further study regarding the factors behind this rise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.